文献速递妇科肿瘤乳腺癌

PI3K通路抑制剂BKM120与口服PARP抑制剂奥拉帕利联合治疗高级别浆液性卵巢癌和乳腺癌的I期剂量递增研究

Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.
PubMed 文献 · Ann Oncol · 2017-01-01

基于小鼠模型的临床前协同作用,开展I期试验确定BKM120与奥拉帕利联合的最大耐受剂量(MTD)、毒性、药代动力学和反应生物标志物。69例可评估患者(乳腺癌24例,卵巢癌46例;35例胚系BRCA突变)接受治疗,MTD为BKM120 50 mg每日一次联合奥拉帕利300 mg每日两次;在乳腺癌和卵巢癌、gBRCAm和gBRCAwt患者中均观察到抗癌活性。

要点

  • BKM120与奥拉帕利可联合给药,但需降低BKM120剂量。
  • MTD为BKM120 50 mg每日一次联合奥拉帕利300 mg每日两次。
  • 在gBRCAm和gBRCAwt患者中均观察到临床获益。

核心结论

  • BKM120与奥拉帕利可联合给药,但联合方案需要降低BKM120剂量。

研究设计与样本

  • I期剂量递增研究,采用3+3设计,主要目的为确定联合方案MTD,次要目的为定义毒性、活性和药代动力学特征。
  • 入组复发乳腺癌或卵巢癌患者,70例入组中69例接受研究治疗,1例因不符合入组标准从未接受研究治疗;乳腺癌24例,卵巢癌46例;35例携带胚系BRCA突变。
  • 在MTD水平为每种癌症设置剂量扩展队列。

主要发现

  • 在DL0(BKM120 60 mg联合奥拉帕利100 mg每日两次)观察到2例剂量限制性毒性(3级转氨酶升高和高血糖)。
  • MTD确定为BKM120 50 mg每日一次联合奥拉帕利300 mg每日两次(DL8)。
  • 其他剂量限制性毒性包括3级抑郁和转氨酶升高,发生于第2周期早期(DL7)。
  • 在乳腺癌和卵巢癌患者中、在gBRCAm和gBRCAwt患者中均观察到抗癌活性。

关键数值与推荐

  • MTD:BKM120 50 mg每日一次联合奥拉帕利300 mg每日两次(DL8)。
  • DL0(BKM120 60 mg联合奥拉帕利100 mg每日两次)观察到2例剂量限制性毒性:3级转氨酶升高和高血糖。
  • DL7观察到其他剂量限制性毒性:3级抑郁和转氨酶升高,发生于第2周期早期。

临床怎么用

  • BKM120与奥拉帕利可联合给药,但联合方案需要降低BKM120剂量。
  • 作者认为需要随机II期研究进一步明确PI3K/PARP抑制剂联合方案与单用PARP抑制剂相比的疗效。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Based upon preclinical synergy in murine models, we carried out a phase I trial to determine the maximum tolerated dose (MTD), toxicities, pharmacokinetics, and biomarkers of response for the combination of BKM120, a PI3K inhibitor, and olaparib, a PARP inhibitor. PATIENTS AND METHODS: Olaparib was administered twice daily (tablet formulation) and BKM120 daily on a 28-day cycle, both orally. A 3 + 3 dose-escalation design was employed with the primary objective of defining the combination MTD, and secondary objectives were to define toxicities, activity, and pharmacokinetic profiles. Eligibility included recurrent breast (BC) or ovarian cancer (OC); dose-expansion cohorts at the MTD were enrolled for each cancer. RESULTS: In total, 69 of 70 patients enrolled received study treatment; one patient never received study treatment because of ineligibility. Twenty-four patients had BC; 46 patients had OC. Thirty-five patients had a germline BRCA mutation (gBRCAm). Two DLTs (grade 3 transaminitis and hyperglycemia) were observed at DL0 (BKM120 60 mg/olaparib and 100 mg b.i.d.). The MTD was determined to be BKM120 50 mg q.d. and olaparib 300 mg b.i.d. (DL8). Additional DLTs included grade 3 depression and transaminitis, occurring early in cycle 2 (DL7). Anticancer activity was observed in BC and OC and in gBRCAm and gBRCA wild-type (gBRCAwt) patients. CONCLUSIONS: BKM120 and olaparib can be co-administered, but the combination requires attenuation of the BKM120 dose. Clinical benefit was observed in both gBRCAm and gBRCAwt pts. Randomized phase II studies will be needed to further define the efficacy of PI3K/PARP-inhibitor combinations as compared with a PARP inhibitor alone.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Matulonis UA, Wulf GM, Barry WT, et al. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Ann Oncol. 2017. PMID: 27993796. doi:10.1093/annonc/mdw672

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。